68ga-nota-mal-cys39-exendin-4
Insulinoma
Nanjing First Hospital, Nanjing Medical UniversityradiopharmaceuticalEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Insulinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Vanderbilt-Ingram Cancer Center | Phase 2 | BB |
Everolimus Emory University | Phase 2 | B |
Regorafenib University of Southern California | Phase 2 | B |
Temsirolimus National Cancer Institute (NCI) | Phase 2 | B |
gw786034 National Cancer Institute (NCI) | Phase 2 | B |
View all 21 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →